News

There is no compelling evidence to suggest any medication increases the risk of developing amyotrophic lateral sclerosis (ALS), according to a review of published studies. If anything, classes of drugs including anti-hypertensives, cholesterol-lowering statins, aspirin, and oral contraceptives may be associated with a lower risk of ALS, although several…

Cellenkos will soon launch two Phase 1 clinical trials to investigate the safety and potential efficacy of its regulatory T-cell-based — Treg cell — therapy CK0803 for amyotrophic lateral sclerosis (ALS). The biotech’s announcement follows the approval, by the U.S. Food and Drug Administration (FDA), of its investigational…

Early treatment with CNM-Au8 continues to demonstrate survival benefits in people with amyotrophic lateral sclerosis (ALS) compared with those who started treatment nine months later, according to an update from its developer, Clene Nanomedicine. The updated results come from the RESCUE-ALS Phase 2 trial (NCT04098406) and its open-label…

The U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have forged a partnership that seeks to advance both the understanding of rare neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and the development of potential treatments. The public-private collaboration, called the Critical Path…

Early treatment with Biogen’s experimental therapy tofersen slows disease progression in people with amyotrophic lateral sclerosis (ALS) associated with SOD1 gene mutations, compared with patients who started treatment after a six-month delay, according to findings from a Phase 3 trial and its open-label extension study. These benefits…

Researchers at Brigham and Women’s Hospital (BWH) have received a grant from the ALS Association to study foralumab nasal spray as a potential treatment for amyotrophic lateral sclerosis (ALS). The Lawrence & Isabel Barnett Drug Development Program grant was awarded to the Ann Romney Center for Neurologic…

The treatment development company Verge Genomics — known for its all-in-human artificial intelligence platform — has been named among the “Fierce 15” by daily email newsletter Fierce Biotech. Verge’s inclusion by the web resource in the 20th annual Fierce 15 listing, announced in a company press release,…

PrimeC, an experimental combination treatment for amyotrophic lateral sclerosis (ALS) being developed by NeuroSense Therapeutics, was well tolerated and lowered disease biomarkers in an open-label Phase 2 clinical trial. That’s according to the study, “Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS,” published…

RT001, an investigational treatment for amyotrophic lateral sclerosis (ALS), shows promising signs that it can slow disease progression, particularly among patients with more severe disease, according to data from a completed Phase 2 pilot trial. While these findings indicate improvements in patients on RT001 treatment, statistical significance was…

Amylyx Pharmaceuticals has donated data from the CENTAUR Phase 2 trial to the PRO-ACT database — the largest collection ever compiled of de-identified amyotrophic lateral sclerosis (ALS) patient records from clinical trials. CENTAUR (NCT03127514) evaluated the safety and efficacy of Amylyx’s investigational treatment AMX0035 against a placebo…